Technical Perspectives on Medical Equipment Stocks -- Prestige Brands, Second Sight Medical Products, Senseonics, and Varian Medical Systems

Monday, February 26, 2018 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 26, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community.  Today we are offering reports on PBH, EYES, SENS, and VAR which can be accessed for free by signing up to This morning, covers the Medical Appliances and Equipment industry, which
comprises companies that are engage in the manufacture of medical instruments, such as dental and surgical appliances. Under review today are: Prestige Brands Holdings Inc. (NYSE: PBH), Second Sight Medical Products Inc. (NASDAQ: EYES), Senseonics Holdings Inc. (NYSE AMER: SENS), and Varian Medical Systems Inc. (NYSE: VAR). All you have to do is sign up today for this free limited time offer by clicking the link below.

Prestige Brands Holdings

Tarrytown, New York headquartered Prestige Brands Holdings Inc.'s stock finished last Friday's session 0.43% higher at $35.15. A total volume of 524,925 shares was traded. The Company's shares are trading below their 50-day moving average by 16.17%. Additionally, shares of Prestige Brands, which through its subsidiaries, markets, sells, manufactures, and distributes over-the-counter healthcare and household cleaning products in North America, Australia, and internationally, have a Relative Strength Index (RSI) of 35.32.  

On February 01st, 2018, Prestige Brands reported financial results for its Q3 and nine months ended December 31st, 2017. For Q3 FY18, revenues were $270.6 million, gross profit margin was 54.6%, and net income totaled $314.8 million. For the first nine months of FY18, revenues were $785.2 million, gross profit margin was 55.4%, and net income totaled $379.3 million. Get the full research report on PBH for free by clicking below at:

Second Sight Medical Products

On Friday, shares in Sylmar, California headquartered Second Sight Medical Products Inc. ended the session 2.56% higher at $1.60. The stock recorded a trading volume of 329,310 shares. The Company's shares have surged 40.35% in the previous three months. The stock is trading 17.25% above its 200-day moving average. Moreover, shares of the Company have an RSI of 39.42.  

On February 16th, 2018, Second Sight Medical Products announced market entry into Singapore, with the first patient implanted with the Company's Argus® II Retinal Prosthesis System. The implantation was facilitated by the Company's exclusive distribution partner in Singapore, Mandarin Opto-Medic Co Pte Ltd. Access the free research report on EYES now by signing up at:

Senseonics Holdings

Germantown, Maryland headquartered Senseonics Holdings Inc.'s shares jumped 9.70%, closing the session at $2.94. A total volume of 540,754 shares was traded, which was above their three months average volume of 429,550 shares. The stock has gained 2.44% in the last month, 8.49% over the previous three months, and 26.72% over the past year. Shares of the Company are trading 7.00% and 18.13% above their 50-day and 200-day moving averages, respectively. Additionally, Senseonics' stock has an RSI of 62.26.  

On February 20th, 2018, Senseonics announced that people with diabetes using the Eversense® brand Continuous Glucose Monitoring Systems in EMEA markets now have the option to invite others to remotely view their real-time glucose readings and alerts from anywhere. The updated Eversense® app with remote monitoring allows up to five family members or friends to use Eversense® NOW, a remote monitoring application that automatically updates and displays glucose data sent from the Eversense system every five minutes to a mobile device. Are you already registered with Wall St. Equities? Do so now for free, and get the report on SENS at:

Varian Medical Systems

Last Friday at the close, shares in Palo Alto, California headquartered Varian Medical Systems Inc. recorded a trading volume of 313,977 shares. The stock ended the session 1.11% higher at $121.17. The Company's shares have advanced 7.18% in the past month, 11.78% over the previous three months, and 44.20% over the past year. The stock is trading above its 50-day and 200-day moving averages by 5.24% and 14.06%, respectively. Furthermore, shares of the Company, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 56.66.  

On February 22nd, 2018, Varian Medical Systems (VAR) announced that it has acquired privately-held, Montreal-based Evinance Innovation, Inc., a clinical decision support software company. This acquisition expands the capabilities of VAR's 360 Oncology™ care management platform by tightly integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelines. Aspiring Member, please take a moment to register below for your free research report on VAR at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store